Credit Suisse Ag Nurix Therapeutics, Inc. Transaction History

Credit Suisse Ag

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$7.86 - $10.08 $49,117 - $62,989	-6,249 Reduced 10.67%	52,328 $411,000
Q2 2023 Aug 11, 2023	BUY	$8.7 - $13.28 $271,239 - $414,030	31,177 Added 113.78%	58,577 $585,000
Q1 2023 May 10, 2023	BUY	$8.56 - $13.26 $77 - $119	9 Added 0.03%	27,400 $243,000
Q4 2022 Feb 13, 2023	SELL	$9.86 - $14.59 $14,385 - $21,286	-1,459 Reduced 5.06%	27,391 $300,000
Q3 2022 Nov 10, 2022	BUY	$12.33 - $19.81 $163,138 - $262,106	13,231 Added 84.71%	28,850 $376,000
Q2 2022 Aug 12, 2022	BUY	$7.88 - $14.82 $9,022 - $16,968	1,145 Added 7.91%	15,619 $197,000
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $10,080 - $23,097	779 Added 5.69%	14,474 $203,000
Q4 2021 Feb 14, 2022	SELL	$26.43 - $34.5 $79 - $103	-3 Reduced 0.02%	13,695 $396,000
Q3 2021 Nov 12, 2021	BUY	$22.71 - $36.69 $76,873 - $124,195	3,385 Added 32.82%	13,698 $411,000
Q2 2021 Aug 16, 2021	BUY	$24.21 - $35.89 $11,790 - $17,478	487 Added 4.96%	10,313 $273,000
Q1 2021 May 14, 2021	SELL	$26.98 - $50.17 $214,652 - $399,152	-7,956 Reduced 44.74%	9,826 $306,000
Q4 2020 Feb 12, 2021	BUY	$22.85 - $48.44 $406,318 - $861,360	17,782 New	17,782 $584,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $923M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.